Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical trials: present and future
Autore:
Mitsumoto, H;
Indirizzi:
Columbia Presbyterian Med Ctr, Eleanor & Lou Gehrig MDA ALS Ctr, New York,NY 10032 USA Columbia Presbyterian Med Ctr New York NY USA 10032 New York,NY 10032 USA
Titolo Testata:
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS
, volume: 2, anno: 2001, supplemento:, 1
pagine: S10 - S14
SICI:
1466-0822(200103)2:<S10:CTPAF>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMYOTROPHIC-LATERAL-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; MOTOR-NEURON DISEASE; CILIARY NEUROTROPHIC FACTOR; GROWTH-FACTOR-I; NATURAL-HISTORY; ALS; GABAPENTIN; RILUZOLE; GDNF;
Keywords:
amyotrophic lateral sclerosis; animal models; clinical trials;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Mitsumoto, H Columbia Univ Coll Phys & Surg, Dept Neurol, 710 W 168th St, New York, NY 10032 USA Columbia Univ Coll Phys & Surg 710 W 168th St New York NY USA 10032
Citazione:
H. Mitsumoto, "Clinical trials: present and future", AMYOTROPH L, 2, 2001, pp. S10-S14

Abstract

The past decade has seen a major expansion of clinical trials in amyotrophic lateral sclerosis (ALS), However, the perfectly-designed ALS trial remains elusive. Attempts to track the progression of the disease: are: affectedby continual improvements in the care of patients. Comparing the effectiveness of different drugs is difficult because different primary endpoints are: used in different studies. We also need to decide how much benefit we are aiming to achieve when studying a new treatment. The interpretation of animal models has also proved problematic, with results not being replicated in human studies. Moreover, promising phase I/II trial results have often not been confirmed by phase III studies, Our patients, meanwhile, are anxious to try any medication that may help, The ALS research community has learned a great deal from past trials and this will be greatly beneficial when evaluating the novel and combination therapies currently being developed. Effort must also be directed towards the search for objective markers for ALS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 06:26:59